Hemostatic Effect of Intrauterine Instillation Of Tranexamic Acid In Hysteroscopic Myomectomy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03122782|
Recruitment Status : Unknown
Verified March 2017 by Hajer Soliman, Ain Shams University.
Recruitment status was: Not yet recruiting
First Posted : April 21, 2017
Last Update Posted : June 29, 2017
Randomized Controlled Clinical Trial.
The study population will be a consecutive series of participants attending the Early Cancer Detection Unit (ECDU) at Ain Shams University Maternity Hospital.
80 women who are scheduled to undergo a hysteroscopic myomectomy will be included and will be randomized into two groups:
Group A: women will undergo a hysteroscopic myomectomy with the use of (TXA) Kapron in the distention medium
Group B: women will undergo hysteroscopic myomectomy with the use of placebo(normal saline in the distention medium).
Randomization will be performed using a Computer-generated randomization system.
The allocated groups will be concealed in serially-numbered sealed opaque envelopes that will only be opened after recruitment.
Patient allocation will be performed prior to the induction of anesthesia by an independent person, who will not otherwise be involved in this study.
The trial will be appropriately blinded; the participants, outcome assessors and the surgeon performing the procedure will be blinded to the medication type, which will be used inside the distention medium.
Therefore, this study will be a randomized double blind prospective clinical
- Informed written consent obtained from the participant.
- Personal history
- Menstrual history
- Detailed obstetric history
- Surgical intervention especially uterine surgeries and any post-operative complication
- History of drug intake, especially hormonal treatment or anticoagulant therapy.
- Routine preoperative investigations in addition to a serum pregnancy test if pregnancy is suspected.
- Physical examination including general, abdominal and pelvic examination.
- Hysteroscopy will be performed in the early proliferative phase using normal saline as a distention medium.
Only in intervention group (TXA group) KAPRON (Tranexamic acid) will be added to the injected media.
- In intervention group 500 mg of Kapron for every 500 ml of distending media will be added.
- In the control group, placebo .i.e. ,normal saline in the same form will be injected inside every 500 ml of the distention medium.
- The trial will be appropriately blinded; the participants, outcome assessors and the surgeon performing the procedure will be blinded to the medication type, which will be used inside the distention medium. Therefore, our study will be a randomized double blind prospective clinical trial.
- Intraoperative bleeding and quality of view will be observed.
- A blood sample will be taken from each participant in both groups after 24 hours from the end of the operation for both hemoglobin and hematocrit levels.
Types of outcome measures:
Primary outcome measures:
Estimated Blood loss defined as comparing the hematocrit and hemoglobin at base line (preoperative ) and 24 hours after surgery with the Tranexamic acid compared to the control group.
Secondary outcome measures:
The quality of view, duration of surgery, the volume of injected media, intraoperative complications and the success of the completion of the operation will be secondary outcomes.
|Condition or disease||Intervention/treatment||Phase|
|Surgical Blood Loss Fibroid||Drug: Topical application Tranexamic acid Drug: Placebo (Normal saline)||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||80 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Hemostatic Effect of Intrauterine Instillation Of Tranexamic Acid In Hysteroscopic Myomectomy|
|Estimated Study Start Date :||August 1, 2017|
|Estimated Primary Completion Date :||August 2017|
|Estimated Study Completion Date :||January 2018|
Active Comparator: Tranexamic acid (TXA) Group
Subjects in the Tranexamic acd (TXA) group will receive intrauterine instillation of 500 mg (100mg/ml) Tranexamic acid per 500 ml normal salin (distention medium) during Hysteroscopic Myomectomy.
Drug: Topical application Tranexamic acid
Tranexamic acid (TXA) will be injected to distinction media during hysteroscopy in myomectomy
Other Name: KAPRON (AMOUN Pharmaceutical co.)
Placebo Comparator: Normal Saline (control group)
Subjects in the control group will receive 500 ml intrauterine instillation of normal saline with the distention medium (normal saline) during Hysteroscopic Myomectomy.
Drug: Placebo (Normal saline)
5ml of normal saline will be added to every 500 ml of distension media
- Estimated blood loss by comparing changes in hemoglobin level [ Time Frame: 24 Hours ]Estimated blood loss by comparing changes in hemoglobin level before hysteroscopic myomectomy (preoperative) and 24 hours after hysteroscopic myomectomy (postoperative) in Tranexamic acid group comparing to the control group
- Estimated blood loss by comparing changes in hematocrit level [ Time Frame: 24 hours ]Estimated blood loss by comparing changes in hematocrit level before hysteroscopic myomectomy (preoperative) and 24 hours after hysteroscopic myomectomy (postoperative) in the Tranexamic acid group comparing to the control group
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03122782
|Contact: Radwa Ali Rasheedy, MD||01283492979||Radwaebed@yahoo.com|
|Study Chair:||Ahmed Khairyy Makled, MD||Ain Shams University|
|Study Chair:||Amgad Said Abu-Gamra, MD||Ain Shams University|
|Study Director:||Radwa Ali Rasheedy, MD||Ain Shams University|
|Principal Investigator:||Hajer Giuma Soliman, M.B.B.CH||Ain Shams University|